Axon-reflex cutaneous vasodilatation is impaired in type 2 diabetic patients receiving chronic low-dose aspirin

Microvascular Research

Volumn 78, Issue 2, 2009, Pages 218-223

  Rousseau, Pascal ^a,c   Mahé, Guillaume ^a,c   Fromy, Bérengère ^b   Ducluzeau, Pierre Henri ^a   Saumet, Jean Louis ^a,b   Abraham, Pierre ^a,c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSERM   (France)

Author keywords

Current stimulation; Diabetes; Iontophoresis; Salicylic acid; Small fiber neuropathy; Vasodilatation

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITROPRUSSIDE SODIUM;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DISABILITY; GALVANIC CURRENT; HUMAN; HYPEREMIA; HYPOTHESIS; IONTOPHORESIS; LOW DRUG DOSE; NERVE FIBER; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCEPTIVE THRESHOLD; PRIMARY PREVENTION; PRIORITY JOURNAL; REFLEX; SKIN BLOOD VESSEL; TEMPERATURE; VASODILATATION; VIBRATION;

ACETYLCHOLINE; ASPIRIN; AXONS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; FEMALE; HUMANS; HYPEREMIA; IONTOPHORESIS; MALE; MIDDLE AGED; NITROPRUSSIDE; VASODILATION; VASODILATOR AGENTS;

EID: 68349139692     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2009.06.005     Document Type: Article

References (35)

1. Report and recommendations of the San Antonio Conference on Diabetic Neuropathy. Consensus statement. Diabetes 37 (1988) 1000-1004
2. Abou-Elenin K., et al. The effect of aspirin and various iontophoresis solution vehicles on skin microvascular reactivity. Microvasc. Res. 63 (2002) 91-95
3. Ali Z., et al. The extent of small fibre sensory neuropathy in diabetics with plantar foot ulceration. J. Neurol. Neurosurg. Psychiatry 52 (1989) 94-98
4. Berliner M.N. Skin microcirculation during tapwater iontophoresis in humans: cathode stimulates more than anode. Microvasc. Res. 54 (1997) 74-80
5. Buse J.B., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30 (2007) 162-172
6. Caballero A.E., et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48 (1999) 1856-1862
7. Durand S., et al. Current-induced vasodilation during water iontophoresis (5 min, 0.10 mA) is delayed from current onset and involves aspirin sensitive mechanisms. J. Vasc. Res. 39 (2002) 59-71
8. Durand S., et al. Vasodilatation in response to repeated anodal current application in the human skin relies on aspirin-sensitive mechanisms. J. Physiol. 540 (2002) 261-269
9. Durand S., et al. Break excitation alone does not explain the delay and amplitude of anodal current-induced vasodilatation in human skin. J. Physiol. 542 (2002) 549-557
10. Durand S., et al. Oral single high-dose aspirin results in a long-lived inhibition of anodal current-induced vasodilatation. Br. J. Pharmacol. 137 (2002) 384-390
11. Durand S., et al. Prostaglandins participate in the late phase of the vascular response to acetylcholine iontophoresis in humans. J. Physiol. 561 (2004) 811-819
12. Fegan P.G., et al. Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy. Diabet. Med. 22 (2005) 1670-1676
13. Fromy B., et al. Non-nociceptive capsaicin-sensitive nerve terminal stimulation allows for an original vasodilatory reflex in the human skin. Brain Res. 811 (1998) 166-168
14. Fromy B., et al. Progressive calibrated pressure device to measure cutaneous blood flow changes to external pressure strain. Brain Res. Brain Res. Protoc. 5 (2000) 198-203
15. Hamdy O., et al. Contribution of nerve-axon reflex-related vasodilation to the total skin vasodilation in diabetic patients with and without neuropathy. Diabetes Care 24 (2001) 344-349
16. Holowatz L.A., and Kenney W.L. Chronic low-dose aspirin therapy attenuates reflex cutaneous vasodilation in middle-aged humans. J. Appl. Physiol. 106 (2009) 500-505
17. Johnstone M.T., et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88 (1993) 2510-2516
18. Kato M., et al. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 102 (2000) 2607-2610
19. Koitka A., et al. Impaired pressure-induced vasodilation at the foot in young adults with type 1 diabetes. Diabetes 53 (2004) 721-725
20. Nicolucci A., et al. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur. Heart J. 28 (2007) 1925-1927
21. Norgren L., et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur. J. Vasc. Endovasc. Surg. 33 Suppl. 1 (2007) S1-S75
22. O'Kane P.D., et al. Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment. Cardiovasc. Res. 59 (2003) 152-159
23. Pitei D.L., et al. NO-dependent smooth muscle vasodilatation is reduced in NIDDM patients with peripheral sensory neuropathy. Diabet. Med. 14 (1997) 284-290
24. Rith-Najarian S., et al. Reducing lower-extremity amputations due to diabetes. Application of the staged diabetes management approach in a primary care setting. J. Fam. Pract. 47 (1998) 127-132
25. Rousseau A., et al. Hyperoxia decreases cutaneous blood flow in high-perfusion areas. Microvasc. Res. 74 (2007) 15-22
26. Rousseau P., et al. Platelet inhibition by low-dose aspirin but not by clopidogrel reduces the axon-reflex current-induced vasodilation in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294 (2008) R1420-R1426
27. Schmiedel O., et al. Microalbuminuria in type 2 diabetes indicates impaired microvascular vasomotion and perfusion. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H3424-H3431
28. Shrikhande G., et al. Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation. J. Vasc. Surg. 43 (2006) 760-770 discussion 770-1
29. Steinberg H.O., et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 97 (1996) 2601-2610
30. Tartas M., et al. Early vasodilator response to anodal current application in human is not impaired by cyclooxygenase-2 blockade. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H1668-H1673
31. Tartas M., et al. Anodal current intensities above 40 microA interfere with current-induced axon-reflex vasodilatation in human skin. J. Vasc. Res. 41 (2004) 261-267
32. Weststrate J.T., et al. The clinical relevance of the Waterlow pressure sore risk scale in the ICU. Intensive Care Med. 24 (1998) 815-820
33. Williams S.B., et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 27 (1996) 567-574
34. World Health Organization. D. o. N.D. S., Report of a WHO Consultation, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1 Diagnosis and classification of diabetes mellitus (1999), Geneva
35. Yvonne-Tee G.B., et al. Reproducibility of different laser Doppler fluximetry parameters of postocclusive reactive hyperemia in human forearm skin. J. Pharmacol. Toxicol. Methods 52 (2005) 286-292